Identification of an Optimal Population for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Mature T and NK Cell Neoplasms

Abstract

Background/Aim: The prognosis of mature T and natural killer (NK) cell neoplasms still remains dismal, despite the advancements in the understanding of the heterogeneous features of these diseases. As allogeneic stem cell transplantation (alloSCT) is an attractive salvage option for relapsed/refractory patients, we conducted this study to identify those who might benefit the most from alloSCT. Patients and Methods: This was a retrospective, single-center, longitudinal cohort study of patients who received alloSCT between December 2019 and January 2000. Results: The median relapse-free survival and overall survival were 4.4 and 10.0 months, respectively. Disease control status at alloSCT and number of previous treatments were associated with survival outcomes. The conditioning intensity did not significantly alter survival. Conclusion: AlloSCT offers a cure chance for selected relapsed or refractory T and NK cell neoplasms, especially when used early and the disease is well controlled prior to transplantation. Patients and MethodsStudy design and subjects. This was a retrospective, longitudinal cohort study of patients with mature T and NK cell neoplasms aged older than 18 years who received alloSCT at Seoul National University Hospital between January 2000 and December 2019. The diagnosis and classification of mature T and NK cell neoplasms were performed according to the World Health Organization criteria at the time of diagnosis (1, 8, 9). Initially, 45 patients with mature 2379 This article is freely accessible online.